CLAIMS

1. Crystalline Form A of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, having an X-ray powder diffraction pattern comprising peaks at 18.1, 20.1, and 22.3 degrees 2θ±0.2 degrees 2θ.

2. A pharmaceutical composition comprising the crystalline Form A of claim 1.

3. Crystalline Form B of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, having an X-ray powder diffraction pattern comprising peaks at 16.2, 18.2, and 19.2 degrees 2θ±0.2 degrees 2θ.

4. A pharmaceutical composition comprising the crystalline Form B of claim 3.

5. Crystalline Form C of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, having an X-ray powder diffraction pattern comprising peaks at 18.0, 20.0, and 21.0 degrees 2θ±0.2 degrees 2θ.

6. A pharmaceutical composition comprising the crystalline Form C of claim 5.

7. Crystalline Form D of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, having an X-ray powder diffraction pattern comprising peaks at 13.4, 21.0, and 23.8 degrees 2θ±0.2 degrees 2θ.

8. A pharmaceutical composition comprising the crystalline Form D of claim 7.

9. Crystalline Form E of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, having an X-ray powder diffraction pattern comprising peaks at 17.8, 21.3, and 22.8 degrees 2θ±0.2 degrees 2θ.

10. A pharmaceutical composition comprising the crystalline Form E of claim 9.

11. The crystalline Form A of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at 9.9, 19.9, and 24.7 degrees 2θ±0.2 degrees 2θ.

12. The crystalline Form B of claim 3, wherein the X-ray powder diffraction pattern further comprises peaks at 15.1, 18.7, and 20.1 degrees 2θ±0.2 degrees 2θ.

13. The crystalline Form C of claim 5, wherein the X-ray powder diffraction pattern further comprises peaks at 12.3, 16.8, and 25.5 degrees 2θ±0.2 degrees 2θ.

14. The crystalline Form D of claim 7, wherein the X-ray powder diffraction pattern further comprises peaks at 18.3, 26.7, and 29.5 degrees 2θ±0.2 degrees 2θ.

15. The crystalline Form E of claim 9, wherein the X-ray powder diffraction pattern further comprises peaks at 15.8, 18.4, and 21.9 degrees 2θ±0.2 degrees 2θ.

16. A compound of any one of claims 1, 3, 5, 7, 9 and 11-15 or a pharmaceutical composition of any one of claims 2, 4, 6, 8, and 10 for use in therapy.

17. Use of a compound of any one of claims 1, 3, 5, 7, 9, and 11-15 or a pharmaceutical composition of any one of claims 2, 4, 6, 8, and 10 in the manufacture of a medicament for treating pain, neurological disorders, anxiety, inflammatory bowel disease, neuropathic pain or the proliferation and migration of cancer cells in a subject.